Bladder Cancer News and Research

Latest Bladder Cancer News and Research

WHO targets workplace related lung cancer, mesothelioma and bladder cancer

According to the World Health Organisation (WHO) more than 200,000 people die each year from cancers related to their workplaces, mainly from inhaling asbestos fibers and second-hand tobacco smoke.

29 Apr 2007

Why bladder cancer hits more men than women

Scientists have discovered one of the reasons why bladder cancer is so much more prevalent in men than women: A molecular receptor or protein that is much more active in men than women plays a role in the development of the disease.

21 Apr 2007

Aspirin use linked to moderate drop in cancer risk

A new American Cancer Society study finds men and women who used adult-strength aspirin (325 mg or more) daily for five or more years had an approximately 15 percent lower rate of developing any cancer than those who did not use aspirin.

20 Apr 2007

Indevus Pharmaceuticals submits supplemental NDA for VALSTAR

Indevus Pharmaceuticals has announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to reintroduce VALSTAR in the United States.

20 Apr 2007

Aspirin may modestly reduce cancer risk

A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.

18 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

Advanced age associated with poorer bladder cancer-specific survival in radical cystectomy patients

Traditional wisdom taught in urological residency has been that healthy octogenarians with bladder cancer may be offered radical cystectomy without a significantly increased incidence of postoperative complications.

18 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

CuraGen announces results with Belinostat and Velafermin

CuraGen Corporation has announced that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007.

15 Apr 2007

Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display

Efforts to create nanoparticles that deliver anticancer drugs or imaging agents to tumors while avoiding healthy cells are often stymied by a lack of known tumor targets, that is, molecules found on the surface of malignant cells but not healthy cells.

12 Feb 2007

New testing approach to predict outcome in patients with bladder cancer

A new testing approach has been shown to be effective in identifying patients at the highest risk of cancer relapse after surgery for bladder cancer, say researchers in the February issue of The Lancet Oncology.

29 Jan 2007

WHO unveils new strategy to fight some of the most neglected tropical diseases

The World Health Organization (WHO) and a group of more than 25 partner organizations unveiled a new strategy to fight some of the most neglected tropical diseases that destroy the lives and health of poor people.

26 Oct 2006

Black people with bladder cancer more likely to die of the disease than white

Black patients with bladder cancer are 35 percent more likely to die of the disease than white patients, according to a new study from the University of Michigan Comprehensive Cancer Center.

21 Sep 2006

Schering-Plough to pay $435M and plead guilty to conspiracy

Schering-Plough on Tuesday agreed to pay $435 million and plead guilty to criminal conspiracy charges to settle a federal investigation into the company's marketing practices and Medicaid charges, the AP/Houston Chronicle reports (AP/Houston Chronicle, 8/30).

30 Aug 2006